Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Locoregional Recurrence × ribociclib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Neoplasms 4 Neoplasm Metastasis 4 Neoplasms by Site 2 Melanoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Neuroblastoma 1 Lung Neoplasms 1 Locoregional Recurrence 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 ER+ HER2- Advanced Breast Cancer 1 EGFR-mutant Non-small Cell Lung Cancer 1 Digestive System Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Cystadenocarcinoma, Serous 1 Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies 1

Interventions

ribociclib 1 exemestane 1 Letrozole 1 Fulvestrant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05467891 2026-02-27

RaPhLRR

Hoosier Cancer Research Network

Phase 2 Recruiting

Locoregional Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡